brain to regain functional movement and cognitive processes after neurological
damage and to compensate for loss.
- To understand the mechanisms of disability and recovery, particularly in progressive neurological disorders.
- To evaluate the effectiveness of neurorehabilitation and the use of outcome measures.
- To assess and improve symptomatic management of neurological disorders.
- To develop collaborations between allied health professionals, recognizing the multi-faceted needs of the patient along the neurorehabilitative pathway.
Funded Research Projects
- Imaging research to facilitate new treatments for multiple sclerosis. Funded by the Multiple Sclerosis Society of Great Britain and Northern Ireland
- ‘Sustainable Reporters’, empowering the MS patient community by creating dialogue with leading experts in MS. Funded by the Wellcome Trust
- External insults to the nervous system. Funded by the German Aerospace Center for Health Research – ERA-NET NEURON
- Recent publications from Neurorehabilitation
Motl R, Feinstein A, Sandroff BM, Kwakkel G, Dalgas U, Feinstein A, Heesen C, Feys P, Thompson AJ. The benefits of exercise in patients with multiple sclerosis. Lancet Neurology, accepted for publication.
Scolding NJ, Pasquini M, Reingold SC, Cohen JA, on behalf of the International Conference on Cell-Based Therapies for Multiple Sclerosis. Cell-based therapeutic strategies for multiple sclerosis. A review article. Brain 2017; published online 21July 2017
Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 2017; 389:1357-1366
Thompson AJ. Multiple Sclerosis: the upward trajectory continues. Lancet Neurology 2017; 16(1):10-12 doi: 10.1016/S1474-4422(16)30343-X.
Thompson AJ. Challenge of progressive multiple sclerosis therapy. Current Opinion in Neurology 2017; 30(3):237-240 doi: 10.1097/WCO.0000000000000453.
Bebo BF, Fox RJ, Lee K, Utz U, Thompson A. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis Journal, online 1 March 2017 doi: 10.1177/1352458517698250. [Epub ahead of print]
Cawley N, Tur C, Prados F, Plantone D, Kearney H, Abdel-Aziz K, Ourselin S, Gandini Wheeler-Kingshott CAM, Miller DH, Thompson AJ, Ciccarelli O.Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Multiple Sclerosis Journal, published online 18th May 2017
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, and the MSCOI Study Group, and the European MS Platform. New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal, epub ahead of print, 20 February 2017 doi: 10.1177/1352458517708687.
Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal 2016 Oct;22(11):1386-1396 Epub 2016 May 19.
Freund P, Friston K, Thompson A, Stephan KE, Ashburner J, Bach D, Nagy Z, Helms G, Draganski B, Schwab M, Curt A, Weiskopf N. Embodied neurology: An integrative framework for neurological disorders. Brain 2016; 139(6):1855-1861 doi: 10.1093/brain/aww076. Epub 2016 Apr 21.
Zaratin P, Comi G, Coetzee T, Ramsey K, Smith K, Thompson A, Panzara M. Progressive MS Alliance Industry Forum: maximizing collective impact to enable drug development. Trends in Pharmacological Sciences, Trends Pharamacol Sci. 2016 Oct;37(10):808-10. doi: 10.1016/j.tips.2016.07.005.
* Cawley et al. (2017). Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.